Protein Catagory: Immuneglobulins
Typ: Human
Molecular Weight: 160,000 Da
Immunogen: No
Compound Purity: ≥95% by SDS-PAGE
Applications: In Vitro Diagnostic, Glycoproteomics, ELISA, Cancer, Chromatography Binding, Anaphalaxis, Infection, Autoimmune Diseases, Kidney Injury, Rheumatoid Arthritis
References: - Tsujita, Y., et al., (2018), 'A Severe Anaphylactic Reaction Associated with IgM-Class Anti-Human IgG Antibodies in a Hyper-IgM Syndrome Type 2 Patient', Journal of Clinical Immunology, 38: pp 144–148. Available at: https://doi.org/10.1007/s10875-017-0466-7 - Abreu, R. B., et al., (2020), 'IgA Responses Following Recurrent Influenza Virus Vaccination.', Front. Immunol. 11: pp 902. Available at: doi: 10.3389/fimmu.2020.00902 - Chuzel, L., et al., (2021), 'Combining functional metagenomics and glycoanalytics to identify enzymes that facilitate structural characterization of sulfated N‐glycans', Microb Cell Fact, 20: pp 162. Available at: https://doi.org/10.1186/s12934-021-01652-w -Scarrone, M. et al., (2021), 'Development of anti-human IgM nanobodies as universal reagents for general immunodiagnostics', New BIOTECHNOLOGY 64: pp 9–16. Available at: https://doi.org/10.1016/j.nbt.2021.05.002 - Frontera, E. D., et al., (2018), 'IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells', Breast Cancer Research and Treatment 172: pp 551–560. Available at: https://doi.org/10.1007/s10549-018-4941-5
Product Description: Serum immunoglobulin A (IgA) constitutes the second most abundant antibody class in human plasma (0.4–2.2 mg/mL), existing predominantly as monomeric IgA1 (80%) with lesser IgA2 contributions. Unlike secretory IgA-a dimeric mucosal protector featuring J-chains and a secretory component-serum IgA engages FcαRI (CD89) on myeloid cells to orchestrate systemic immunity. Monomeric serum IgA suppresses inflammation via inhibitory ITAMi signaling, while immune complexes activate phagocytosis, cytokine release, and antibody-dependent cellular cytotoxicity, balancing pathogen clearance and tissue homeostasis. Dysregulation of serum IgA underpins multiple pathologies. Selective IgA deficiency (sIgAD), the most common primary immunodeficiency, elevates risks for recurrent infections and autoimmune disorders like systemic lupus erythematosus (SLE) and celiac disease. Conversely, elevated serum IgA associates with IgA nephropathy, where galactose-deficient IgA1 deposits in renal glomeruli trigger complement-mediated inflammation and progressive kidney failure. Hyper-IgA levels may also signal immunodeficiency syndromes or multiple myeloma, particularly when beta-migrating monoclonal proteins complicate electrophoresis interpretation. The IgA2 subclass, distinguished by reduced sialylation, exhibits heightened pro-inflammatory activity linked to rheumatoid arthritis severity. Clinically, serum IgA quantification aids immunodeficiency diagnosis and myeloma monitoring, where nephelometric assays outperform traditional electrophoresis. Therapeutic strategies targeting FcαRI or aberrant IgA production, such as monoclonal antibodies against B-cell activating factor (BAFF), show promise in autoimmune and renal diseases. Additionally, engineered IgA antibodies are being explored for enhanced neutrophil-mediated tumor cytotoxicity, highlighting its expanding translational potential.
English
Deutsch
